Predicting sentinel lymph node metastasis in breast cancer with lymphoscintigraphy by Noguchi Atsushi et al.
Predicting sentinel lymph node metastasis in
breast cancer with lymphoscintigraphy
著者 Noguchi Atsushi, Onoguchi Masahisa, Ohnishi
Takeshi, Hashizume Terumi, Kajita Akiyoshi,















The type of article: Original article 
 
Predicting sentinel lymph node metastasis in breast cancer with 
lymphoscintigraphy 
 
A short title: Predicting SLN metastasis  
 
Atsushi Noguchi, Masahisa Onoguchi, Takeshi Ohnishi, Terumi Hashizume, Akiyoshi 
Kajita, Masahiro Funauchi, Toshizo Katsuda, Kazuyoshi Motomura 
 
 
A. Noguchi, T. Ohnishi, T. Hashizume, A. Kajita, M. Funauchi 
Department of Nuclear Medicine, Osaka Medical Center for Cancer and Cardiovascular 
Diseases,  
1-3-3 Nakamichi, Higashinari, Osaka, 537-8511, JAPAN  
 
A. Noguchi, M. Onoguchi 
Department of Quantum Medical Technology, Division of Health Sciences, Kanazawa 
University Graduate School of Medical Science, 
5-11-80 Kodatsuno, Kanazawa, 920-0942, JAPAN 
 
T. Katsuda 
Department of Radiological Technology, Seikeikai College of Medical Technology, 4-5-
9 Kouryou nishimachi, Sakai, 590-0026, JAPAN 
 
K. Motomura 
Department of Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases,  
1-3-3 Nakamichi, Higashinari, Osaka, 537-8511, JAPAN 
 
 
Address correspondence and reprint requests to: 
Masahisa Onoguchi  
Department of Quantum Medical Technology, Division of Health Sciences, Kanazawa 
University Graduate School of Medical Science, 
5-11-80 Kodatsuno, Kanazawa, 920-0942, JAPAN 
Phone&Fax: 076-265-2526 
E-mail address; onoguchi@kenroku.kanazawa-u.ac.jp 





Objective   Lymphoscintigraphy is an effective method for detecting sentinel 
lymph nodes (SLNs). However, the rate and degree of SLN detection is not 
uniform. We quantified SLNs detected with lymphoscintigraphy, and 
investigated correlations with factors that may influence detection. We then 
attempted to predict SLN metastasis from lymph node counts, comparing the 
predictions to subsequent biopsy results. 
Methods   We assessed lymph node counts in 100 breast cancer patients in 
whom a single SLN was detected with a fixed lymphoscintigraphy procedure. 
We examined correlations between the counts and factors known to influence 
lymphoscintigraphic SLN detection (age, body mass index, tumor size, and 
presence or absence of metastasis), and determined reference values (lymph 
node counts of 10.0, 19.4 and 53.0) which were used to predict SLN metastasis 
in 100 subsequent patients. The predictions were then compared with the SLN 
biopsy findings. 
Results   SLN counts correlated strongly with the presence or absence of 
metastasis, with metastasis-positive lymph nodes showing significantly lower 
counts than negative nodes (p < 0.001). Prediction of SLN metastasis achieved a 




100% positive predictive value at a reference value of 10.0, and a 100% negative 
predictive value at a reference value of 53.0. At a reference value of 19.4, the 
sensitivity, specificity, and diagnostic accuracy were 77.8%, 73.2%, and 74.0%, 
respectively.  
Conclusions    The SLN counts detected with lymphoscintigraphy were 
significantly lower in metastasis-positive lymph nodes than in metastasis-
negative lymph nodes. This suggests that prediction of SLN metastasis in breast 
cancer is possible using lymphoscintigraphy. 
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 The presence or absence of metastasis in the axillary lymph nodes in 
breast cancer is a key factor for deciding the therapeutic strategy [1]. The 
sentinel lymph node (SLN) reflects the metastatic status of the axillary lymph 
nodes [2-5]. The idea that the absence of SLN metastasis indicates absence of 
metastasis in other axillary lymph nodes is used to decide whether to omit 
axillary lymph node dissection [6, 7], reducing the area of excision and 
enhancing the patient’s quality of life. Diagnosis of SLN metastasis is made 
intraoperatively through biopsy. Thus, it has not been possible to determine 
preoperatively whether axillary lymph node dissection is necessary. 
 Lymphoscintigraphy is currently used preoperatively for SLN 
identification, though not for prediction of SLN metastasis. Previous studies 
have shown that SLN visualization in patients with breast cancer is influenced 
by several factors, including procedural variations [8-12] and such patient 
factors as age, body mass index (BMI), tumor size, and metastasis to the SLN 
[13-15]. While those studies have served to advance the SLN detection rate, the 
detection rates have not been uniform, and the degree of detection has not yet 
been assessed. 




 In this study, lymphoscintigraphy was conducted with a fixed procedure, 
and the degree of SLN detection was quantified by assessing lymph node counts. 
Correlation of the lymph node counts with patient factors showed that the counts 
correlated most strongly with the presence or absence of metastasis. On that 
basis, reference values derived from the lymph node counts were used to attempt 
prediction of SLN metastasis. Finally, the predictions of metastasis were verified 
by comparing them with the SLN biopsy findings. 
 




Materials and Methods 
Patients 
 Participants in the study were T1N0M0 breast cancer patients with a 
tumor size of 20 mm or less and no clinical lymph node metastasis, who 
submitted written informed consent. A total of 557 patients (median age: 56 
years, range: 26-84 years) completed the procedures from August 2003 through 
January 2008.  
 The criteria for inclusion were detection with lymphoscintigraphy of only 
a single SLN, and surgical removal of a single SLN. These criteria were set in 
order to maintain a one-to-one correspondence between detected nodes and 
SLNs removed for biopsy. Correlations between lymph node counts and patient 
factors were investigated in 100 consecutive cases (from August 2003 through 
July 2005, standard patients). The correlations were used to predict SLN 
metastasis in the next 100 consecutive cases (from August 2005 through January 
2008, predicted patients). 
 
Lymphoscintigraphy and SLN Biopsy  
 In each case, lymphoscintigraphy was conducted on the day prior to 




surgical resection of breast cancer using the following procedure. A total volume 
of 45 MBq/0.4 mL of 99mTc-tin colloid was injected at four intradermal sites 
around the tumor. At three hours after injection, the patient was placed in a 
supine position with the upper extremity near the affected area elevated, the 
injection sites were masked with a lead plate, and lymphoscintigraphy was 
performed with an anterior oblique view of 30 degrees. The device used was a 
gamma camera equipped with a low-energy high-resolution collimator (RC2500 
IV, Hitachi Medical Corp., Tokyo, Japan). Static acquisition with a 256 x 256 
matrix was conducted for five minutes. 
 During the surgical resection, the SLN was identified with a gamma probe 
(neo 2000, Neoprobe, Dublin, Ohio, USA) before dissection. The biopsy 
consisted of two pathological diagnoses, using imprint cytology and rapid 
histology. If metastasis was detected in one or both of the diagnoses, the result 
was considered positive; if no metastasis was observed, it was considered 
negative. 
 
Correlation of Lymph Node Counts and Patient Factors 
 To quantify the degree of SLN detection with lymphoscintigraphy, a 




region of interest was set with a threshold value of 50%. The lymph node count 
was defined as the mean count within the region of interest. 
 The patient sets were each divided into two groups at the median values 
of age, BMI, and tumor size. To determine significance with respect to the 
presence or absence of SLN metastasis, the lymph node counts were divided into 
groups of positive and negative cases, and compared. Lymph node counts were 
also compared for the positive and negative groups within each of the groups 
divided by patient factors.  
 The differences between groups were calculated using the unequal 
variance t-test (Welch’s t-test), with P values < 0.05 defined as statistically 
significant. 
 
Metastasis Prediction and Verification of Predictions 
 From the lymph node counts in the 100 correlated cases (the standard 
patients), three reference values were derived for prediction of SLN metastasis: 
the maximum and mean values in the positive groups, and the minimum value in 
the negative groups. In the 100 predicted cases from August 2005, counts equal 
to or higher than the reference values were predicted to be metastasis-negative, 




while those below the reference values were predicted to be metastasis-positive. 




Lymphoscintigraphy and SLN Biopsy 
 Figure 1 shows cases of SLNs with low (a) and high (b) tracer 
accumulations. Figure 1a is metastasis-positive with a lymph node count of 16.6. 
Figure 1b is metastasis-negative with a lymph node count of 135.2. 
 Table 1 lists the characteristics of the standard patients and the predicted 
patients. The median age was 53 and 56 years, respectively; the median BMI 
was 21.7 and 21.6, respectively; and the median tumor size was 15 mm in both 
sets. The patient sets thus had similar characteristics. The number of metastasis-
positive SLN cases among the standard and predicted patients was 25 and 18, 
respectively. 
 
Correlation of Lymph Node Counts and Patient Factors 
 For assessment of patient factors, each patient set was divided into two at 




the age of 53, BMI of 21.7, and tumor size of 15 mm, and differences of lymph 
node counts between the pairs of groups were analyzed. Although there was a 
difference in age between the patient sets (p = 0.0332), no significant differences 
were found in BMI or tumor size. There was a clear difference between the SLN 
metastasis-positive and negative groups (p < 0.0001), with lower counts in the 
positive group (Fig. 2).  
 Comparisons of the lymph node counts between the metastasis-positive 
and negative groups divided in two according to age, BMI, or tumor size, 
revealed significant differences for each pair. The lymph node counts were 
consistently lower in the metastasis-positive groups (Table 2). 
 
Metastasis Prediction and Verification of Predictions 
 Reference values for predicting SLN metastasis were set at 10.0 
(minimum value in the negative group), 19.4 (mean value in the positive group), 
and 53.0 (maximum value in the positive group). For the reference value of 10.0, 
all 11 cases with lymph node counts below 10.0 and a positive prediction were 
found to be metastasis-positive. For the reference value of 53.0, all 28 cases with 
lymph node counts equal to or higher than 53.0 and a negative prediction were 




found to be metastasis-negative (Table 3). Thus, the positive predictive value of 
the reference value 10.0 and the negative predictive value of the reference value 
53.0 were both 100%. For the reference value 19.4, the sensitivity, specificity, 
and diagnostic accuracy were 77.8%, 73.2%, and 74.0%, respectively (Table 4). 
 
Discussion 
 The SLN counts observed in this study were lower in the metastasis-
positive group than in the metastasis-negative group. This finding suggests that 
lymphoscintigraphy may be used preoperatively to predict SLN metastasis. 
 SLN detection with lymphoscintigraphy was associated with procedural 
and patient factors, and correlations were made between the patient factors and 
the degree of detection using a fixed procedure. While a significant difference in 
lymph node counts was observed for age, the difference observed for presence 
or absence of metastasis was even more significant. Higher age, BMI, or tumor 
size tended to correlate with lower lymph node counts, while significant 
differences were clearly observed between these groups according to the 
presence or absence of metastasis (Table 2).  
 SLN detection most strongly reflected the presence or absence of 




metastasis, with lymph node counts being lower in the metastasis-positive group 
than in the negative group. To explain this finding, we may infer that radioactive 
tracer does not accumulate in the metastatic lesion within an SLN. Accordingly, 
metastatic prediction would be possible through lymph node assessment. 
  If readers predict metastasis using lymph node counts, they have to establish 
reference values. Reference values have to be assessed by lymphoscintigraphy with a 
fixed procedure.  In addition, the reference values are assumed to be changeable by an 
institution even when a fixed procedure is applied.  
 We established the reference values reappraised from lymph node counts 
in the 100 cases. When the lymph node count was below 10 (minimum value in 
the negative group), we predicted that SLN would be metastasis-positive. And 
when the lymph node count was higher than 53 (maximum value in the positive 
group), we predicted SLN to be metastasis-negative. In fact, in the present 
investigation of 100 cases, positive metastasis was predicted in all 11 cases with 
low lymph node counts, and negative metastasis was predicted in all 28 cases 
with high lymph node counts, consistent with the diagnoses based on SLN 
biopsies. 
 Wang et al. reported a lower SLN detection rate in patients with 




metastasis to the axillary lymph nodes than in patients with no metastasis, but 
they did not discuss the degree of SLN detection [16]. The present study also 
found lower lymph node counts and less clear SLN detection in the metastasis-
positive group than in the metastasis-negative group, and made a further 
comparative investigation of patients with and without SLN metastasis. 
 Nakashima et al. performed dynamic lymphoscintigraphy using 99mTc-
phytate, and reported that abnormal accumulation was observed near the hot 
spots (SLNs) in the metastasis-positive cases [17]. In that study, patients with 
abnormal accumulation near the SLN were predicted to be metastasis-positive. 
In the present study, no abnormal accumulation was observed near SLNs 
because the tracer was 99mTc-tin colloid, which has a larger particle size than 
99mTc-phytate. As 99mTc-tin colloid takes longer to flow into the lymph channel, 
it is not suitable for dynamic lymphoscintigraphy. Accordingly, for metastatic 
prediction with lymphoscintigraphy using 99mTc tin colloid, lymph node counts 
should be assessed. Whereas Nakashima et al. based the metastatic prediction on 
visual assessment, this study used measurement and quantitative evaluation of 
lymph node counts to improve the accuracy of prediction. 
 Preoperative prediction of SLN metastasis in breast cancer is possible 




with either the dynamic lymphoscintigraphy employed by Nakashima et al., or 
lymphoscintigraphy as used in the current study. Thus, although preoperative 
lymphoscintigraphy was initially explored for the sole objective of SLN 
detection, in the future it will likely provide information useful for metastatic 
prediction. 
 The present study was limited to patients with only a single SLN, and 
there is a need to investigate cases with two or more SLNs in the future. Martin 
et al. have already reported that when metastasis-positive and metastasis-
negative lymph nodes were mixed in patients with multiple SLNs, metastasis 
was found in the lymph nodes with lower counts [18]. This suggests that 
metastatic prediction will also be possible in cases with multiple SLNs. 
 
Conclusion 
 The SLN counts detected with lymphoscintigraphy were significantly 
lower in metastasis-positive lymph nodes than in metastasis-negative lymph 
nodes. This strongly suggests that prediction of SLN metastasis in breast cancer 
is possible using lymphoscintigraphy. 
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Fig. 1: Examples of low (a) and high (b) concentrations in sentinel lymph nodes 
detected with lymphoscintigraphy. The injection sites T were masked with lead plates 
during lymphoscintigraphy. 
 
Fig. 2: Comparisons of lymph node counts between patient sets divided according to 
age, BMI, tumor size, and SLN metastasis. 
 
TABLES 
Table 1: Characteristics of standard patients and predicted patients 
 
Table 2: Comparison of metastasis-positive and metastasis-negative SLN counts in 
groups divided by age, BMI, and tumor size for each patient set 
 
Table 3: Judgment of SLN metastasis with lymphoscintigraphy and results of SLN 
biopsies 
 
Table 4: Comparison of SLN metastasis judgments at each reference value 
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Characteristics Standard patients Predicted patients 
  ( n = 100 ) ( n = 100 ) 
Age (years): Median (Range) 53 (26-77) 56 (32-76) 
BMI: Median (Range) 21.7 (16.6-30.5) 21.6 (17.0-35.4) 
Tumor size (mm): Median (Range) 15 (7-20) 15 (1-20) 
Tumor location (number of cases)   
  Upper outer quadrant 45 54 
  Upper inner quadrant 27 21 
  Lower outer quadrant 21 16 
  Lower inner quadrant 7 8 
  Central 0 1 
SLN metastasis (number of cases)   
  Positive 25 18 








 Factor SLN metastasis   SLN counts p value 
     ( n )         ( n ) minimum maximum mean  
Age, years                  
＞53  （49）  Positive （11） 1.8 36.6 18.06 0.0009
 Negative （38） 10.0 257.0 53.77 
 53  （51） Positive （14） 3.6 53.0 20.36 < 0.0001
 Negative （37） 11.2 346.5 96.15 
BMI     
＞21.7 （50） Positive （11） 1.8 53.0 17.31 < 0.0001
 Negative （39） 11.9 246.2 62.03 
 21.7 （50） Positive （14） 5.8 36.6 20.96 < 0.0001
 Negative （36） 10.0 346.5 88.38 
Tumor size, mm     
＞15 （52） Positive （19） 1.8 53.0 19.53 < 0.0001
 Negative （33） 10.0 260.5 82.89 
 15 （48） Positive  （6） 6.7 28.9 18.80 0.0002









Judgment of SLN metastasis   Results of SLNB 
    Positive （n=18） Negative （n=82） 
Judgment at reference value 10.0    
Metastasis predicted  11 0 
Metastasis not predicted  7 82 
Judgment at reference value 19.4    
Metastasis predicted  14 22 
Metastasis not predicted  4 60 
Judgment at reference value 53.0    
Metastasis predicted  18 54 






















Judgment at reference 
value 10.0 
 61.0 100.0 100.0 92.1 93.0 
Judgment at reference 
value 19.4 
 77.8 73.2 38.9 93.8 74.0 
Judgment at reference 
value 53.0 
 100.0 34.1 25.0 100.0 46.0 
 
 
